Healthcare Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization Updated : November 18, 2020 08:29 PM IST Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 percent. Vaccine was well-tolerated and that side effects were mostly mild to moderate, claims the company. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.